The Non-obese Diabetic (NOD) mouse model for type I diabetes also develops some features of Sjögren’s syndrome (SS). Since the source of the mice and the environment exert a strong influence on diabetes, this study investigated SS development in NOD mice obtained from two vendors. Female NOD mice from The Jackson Laboratory (JAX) and Taconic Biosciences were monitored for blood glucose and pilocarpine-induced salivation. The gut microbiome was analyzed by 16S rRNA sequencing of stool DNA. At euthanasia, serum cytokines and sialoadenitis severity were evaluated. The onset of diabetes was significantly accelerated in JAX mice compared to Taconic mice. Although the gut microbiome between the two groups was distinct, both groups developed sialoadenitis. There was no correlation between the severity of sialoadenitis and reduced saliva production. Instead, salivary gland dysfunction was associated with hyperglycemia and elevation of serum IL1β, IL16, and CXCL13. Our data suggest that inflammatory pathways linked with hyperglycemia are confounding factors for salivary gland dysfunction in female NOD mice, and might not be representative of the mechanisms operative in SS patients. Considering that NOD mice have been used to test numerous experimental therapies for SS, caution needs to be exerted before advancing these therapeutics for human trials.
Reduced fluid secretion by the exocrine salivary and lacrimal glands is a major cause of dry mouth and dry eyes in Sjögren’s syndrome (SS)1. Multiple factors like intrinsic glandular defects, innate immune activation, and adaptive autoimmune responses contribute to the development of glandular dysfunction in SS. The Non-obese Diabetic (NOD) mouse model, primarily developed to study type I diabetes, is extensively used to investigate the pathogenic mechanisms in SS2. Although under a robust genetic control, environmental factors also significantly affect the development of diabetes in the NOD mouse3. The environmental influence is exemplified by studies showing differences in the incidence of hyperglycemia in NOD mice obtained from two different commercial sources, The Jackson Laboratory (JAX) and Taconic Biosciences4.
The NOD mice have been used for several preclinical drug studies for SS5,6,7,8,9,10,11. Since the mice are obtained from different commercial sources or are bred within the investigator’s facility, they are exposed to distinct housing conditions. Thus, it is not surprising to note considerable variations in the incidence, severity, and kinetics of SS in NOD mice. We undertook this study to investigate whether the commercial source of the mice influences the development of SS in NOD mice housed under the same environment.
Our results demonstrate that the NOD mice from JAX had an accelerated onset of diabetes; in contrast, the Taconic mice had a significantly (p = 0.0289) higher severity of salivary gland inflammation. Regardless of the commercial source, mice showed evidence for salivary gland dysfunction, which was strongly associated with hyperglycemia.
Salivary gland dysfunction is associated with hyperglycemia
A previous report in the literature showed a higher incidence of diabetes in the NOD/ShiLtJ (JAX) mice compared to NOD/MrkTac (Taconic) mice4. Our data also showed that by 20 weeks of age, 80% (12/15) of JAX mice were hyperglycemic with blood glucose >250 mg/dL, compared to 42% (8/19) of Taconic mice (see Supplementary Fig. S1). The 16S rRNA sequencing of stool DNA samples revealed a dramatically distinct gut microbiome composition between the two groups of mice, thereby highlighting the role of gut microbiota in diabetes development in NOD mouse (See Supplementary Fig. S2).
To evaluate salivary gland function, we measured pilocarpine-induced saliva production at different time points. In JAX mice, there was a significant (p = 0.0092) drop in mean saliva produced at 16 weeks of age (Fig. 1a). In contrast, Taconic mice showed a modest but significant (p = 0.0415) drop at 18–20 weeks of age (Fig. 1b). The analysis of saliva production in JAX and Taconic mice showed that a majority of the mice showing lower saliva amounts had elevated blood glucose. Hence, saliva amounts between hyperglycemic (blood glucose >250 mg/dL) and normoglycemic (blood glucose <250 mg/dL) mice were compared. At 18–20 weeks of age, mice with high blood glucose had significantly lower mean amount of saliva (67%, p < 0.0001) (Fig. 1c).
In our established method of saliva collection12, to account for any pilocarpine dosage effects, the amount of saliva produced is normalized by the total body weight of the mouse. This is an important consideration since the mouse body weights are liable to change with age over an extended period of time (see Supplementary Fig. S3). However, the saliva data analyzed without the weight normalization also showed the same results (See Supplementary Fig. S3). Further, regardless of the method used, the functional loss in the hyperglycemic mice was identical (67%, p < 0.0001).
Salivary gland inflammation does not correlate with hyperglycemia
The presence of lymphocytic foci in salivary glands is a characteristic feature of SS, which is recapitulated by the NOD mouse model2. To accurately quantify the extent of inflammation in the salivary glands, we determined the area fraction of the salivary gland section occupied by lymphocytic infiltrates (Fig. 2a). The submandibular glands from the Taconic mice had significantly (p = 0.0289) higher inflammation than the JAX mice (Fig. 2b). However, the severity of salivary gland inflammation between mice with or without hyperglycemia was not significantly different (Fig. 2c). In addition, regardless of the mouse source, the severity of inflammation in salivary glands did not correlate with salivary gland dysfunction (Fig. 2d). Instead, the mice showed a trend in increased saliva production with higher % area of inflammation. An analysis including only normoglycemic mice (n = 11) showed a similar trend of higher saliva production correlating with increased inflammation. Again, this correlation failed to reach statistical significance (r = 0.48, p = 0.1506).
Hyperglycemic NOD mice have distinct circulating cytokine profile
To investigate mechanisms responsible for salivary gland dysfunction, a 33-plex assay was used to measure serum cytokine levels in mice with high and low blood glucose (Fig. 3 and see Supplementary Fig. S4). Hyperglycemic mice showed significantly higher levels of IL1β (p = 0.0101), IL16 (p = 0.004), and CXCL13 (p = 0.005), and significantly lower levels of CCL4 (p = 0.008), IL10 (p = 0.0134), and IFNγ (p = 0.023). All three elevated cytokines in the hyperglycemic mice showed a significant inverse correlation between cytokine levels and the amount of saliva produced. In contrast, cytokines elevated in normoglycemic mice showed a modest but statistically significant direct correlation (CCL4: r = 0.5308, p = 0.0075, IL10: r = 0.5216, p = 0.0075 and IFNγ r = 0.4024, p = 0.0461) with saliva production.
Differential gene expression in the submandibular glands of hyperglycemic mice
To investigate the effects of hyperglycemia and elevated cytokine levels on salivary gland gene expression, submandibular glands from Taconic mice (six normoglycemic and six hyperglycemic) were used to analyze RNA expression by employing the nCounter mouse Immunology panel (Fig. 4). Although several genes activated downstream of innate immune pathways showed upregulation, only Nfkbia, Irak2 and C4a met the cut-off for statistical significance.
Systemic autoimmunity, exocrine gland inflammation, reduced tear, and saliva production are hallmarks of SS. Thus, any therapy that aims to treat SS needs to reverse not only the course of an ongoing autoimmune response but also restore the fluid secretion ability of the exocrine glands. The NOD mice develop autoantibodies, severe inflammation in the submandibular glands, and salivary gland dysfunction and have been widely used in SS research2. However, with increasing age, a substantial proportion of female NOD mice develop hyperglycemia limiting the time frame over which SS studies can be performed. The hyperglycemic mice become moribund and have to be removed from the analyses to avoid potentially confounding effects of hyperglycemia on SS phenotype11. The consequence is a considerable limitation in the number of mice evaluated and a skewed representation of data from mice retained in the experiment. In this study, using NOD mice from two distinct commercial sources, we show that salivary gland dysfunction is strongly associated with the onset of hyperglycemia and the systemic elevation of pro-inflammatory cytokines. In addition, our study reaffirms the previously reported dissociation between the severity of sialoadenitis and extent of salivary gland dysfunction in NOD mice13. Surprisingly, despite dramatic differences in the composition of gut microbiome between JAX and Taconic mice, and distinct kinetics of diabetes, both groups developed sialoadenitis.
The role of hyperglycemia in salivary gland dysfunction is well established. Many individuals with diabetes develop xerostomia14. The C57BL/6-Ins2 Akita/J (Akita) mice carry a mutation in Ins2 (insulin 2 gene) and resemble juvenile-onset diabetes mellitus type I15. These mice are hyperglycemic without being autoimmune and they do not show any inflammatory cell infiltrates in their salivary glands. Yet they produce little or no pilocarpine-induced saliva, supporting a role for hyperglycemia in salivary gland dysfunction. Although precise mechanisms responsible for hyperglycemia-induced salivary gland dysfunction are not known, the localized production of ROS16 and alterations in Ca2+ signaling in acinar cells has been proposed to cause functional changes in salivary glands17. In our study, serum levels of IL1β showed the most significant negative correlation (r = −0.7141, p < 0.0001) with saliva production. Furthermore, gene expression studies in salivary glands of hyperglycemic mice (Fig. 4) showed significant upregulation in the expression of Nfkbia (p = 0.0129) and Irak2 (p = 0.0487), which are associated with the IL1R signaling pathway.
A previous study in the NOD mice has demonstrated the role of IFNγ in salivary gland disease18. NOD mice lacking either IFNγ or its receptor (IFNγR) were protected from autoimmune responses targeting the salivary glands. In our study, the importance of IFNγ in salivary gland dysfunction is highlighted in normoglycemic mice, where serum IFNγ levels showed significant negative correlation with saliva amount (r = −0.7366, p = 0.0097) (see Supplemental Fig. S5). However, IL10, an anti-inflammatory cytokine also showed similar negative correlation with saliva amounts (r = −0.8082, p = 0.0037). It should be noted that even in normoglycemic mice, saliva amount shows significant inverse correlation with blood sugar (r = −0.636, p = 0.035). Collectively these data suggest that direct effects of high blood glucose and cytokines on salivary glands might be the contributing factors for glandular dysfunction in NOD mice. A recent study presented evidence for metabolic disorder in SS19. However, whether hyperglycemia contributes to SS pathogenesis can only be evaluated by monitoring SS patients for blood glucose levels.
The NOD mouse has been extensively used to test different therapeutic modalities for SS5,6,7,8,9,10,11. In many instances, treatments are initiated before the development of hyperglycemia. Whether the beneficial effects on SS phenotype were occurring through the regulation of diabetes has been investigated only in a few studies10,11 and remains a critical factor for debate. In this context, a study reporting beneficial effects of resveratrol on SS phenotype suggested that high blood sugar was not a factor for glandular dysfunction in NOD mice10. In this report, at 22 weeks, only 2 out of 10 NOD mice had developed hyperglycemia, and these two hyperglycemic mice were among the lowest saliva producers. Of the 8 normoglycemic mice, only one mouse showed lower saliva production. Thus, the conclusion of a lack of correlation between saliva secretion and blood sugar in this report was not supported by robust data.
Considering these caveats in literature and the data presented in this manuscript, the mechanisms for glandular dysfunction in the NOD mouse, might not accurately represent mechanisms operative in SS patients. Thus, preclinical studies employing NOD mice, particularly for restoration of glandular function, need to be rigorously evaluated before any human clinical trials are undertaken. However, it should be noted that the NOD mouse model has provided valuable information on pathways involved in immune cell infiltration in the salivary glands and has utility to investigate mechanisms involved in this process6,20,21,22. Based on our findings, we would like to suggest that the use of genetically modified NOD mice, which show critical characteristics of SS without developing hyperglycemia23,24, is a valuable alternative for preclinical studies in SS.
All animal experiments were approved by the Oklahoma Medical Research Foundation Institutional Animal Care and Use Committee and followed the recommendations set by the National Institutes of Health, USA. Female NOD/ShiLtJ (The Jackson Laboratory, Bar Harbor, ME, USA) and female NOD/MrkTac (Taconic Biosciences Inc., Germantown, NY, USA) were purchased at four weeks of age and housed in barrier cages under specific pathogen-free conditions. The mice were given the feed provided by the respective animal vendors in their facilities. Only female mice were used in this study.
Non-fasting blood glucose levels were monitored using the Contour next ONE blood glucose monitoring system (Ascensia Diabetes Care US Inc., Parsippany, NJ, USA) and reading of >250 mg/dL was considered hyperglycemic. Moribund mice were euthanized and tissues were collected.
Pilocarpine induced saliva was measured as described previously12.
Analysis of salivary gland Inflammation
Sections (5 μm) of formalin-fixed and paraffin-embedded glands were stained with hematoxylin and eosin. For quantitation of inflammation, H&E stained slides were scanned on an Aperio CS2 digital pathology scanner and image analysis was performed using the Aperio ImageScope software (Leica Biosystems, Buffalo Grove, IL, USA). An aggregate of >50 mononuclear cells within the salivary gland parenchyma was considered a lymphocytic focus. The total area of the salivary gland and the regions occupied by lymphocytic foci were measured. Since none of the sections showed areas of fatty infiltration, no areas within the salivary glands were excluded from the analysis. The results are expressed as % area of inflammation calculated as: (Area of inflammation ÷ Total area of the section) × 100. On an average 9.21 ± 0.8 (mean ± SEM) mm2 of total salivary gland tissue was studied for each mouse.
Sera collected at euthanasia were analyzed for cytokines and chemokines using the 33-Plex Mouse Chemokine Panel (Bio-Rad, Hercules, CA, USA) as described previously25.
Stool samples were collected from the mice at 5–6 weeks of age, and snap-frozen in liquid nitrogen. Stool pellets were shipped to Microbiome Insights (Vancouver, BC, Canada) for 16S rRNA sequencing and analysis. 16Sv4 amplicons generated from stool pellet samples were sequenced on a MiSeq. MiSeq-generated Fastq files were quality-filtered and clustered into 97% similarity operational taxonomic units (OTUs) using the mothur software package [http://www.mothur.org]. The resulting dataset had 9763 OTUs (including those occurring once with a count of 1, or singletons). An average of 43492 quality-filtered reads were generated per sample. High quality reads were classified using Greengenes v. 13_8 as the reference database. The OTUs were aggregated into each taxonomic rank, and the relative abundance of the most abundant ones plotted.
All data were analyzed for Gaussian distribution using the D’Agostino-Pearson omnibus normality test. For analysis of variance between 2 groups, unpaired student’s t-test was used for data fitting Gaussian distribution. For data not fitting Gaussian distribution, a Mann-Whitney test was performed. Both tests were 2 tailed at 95% confidence interval, and a p < 0.05 considered significant. For comparing 3 or more groups either a one-way ANOVA or Kruskal-Wallis test, with Dunn’s multiple comparison was used and a p < 0.05 considered significant. For correlation analysis, either Pearson correlation coefficient (for data fitting normal distribution) or nonparametric Spearman correlation coefficient (for data not fitting normal distribution) was calculated. Both tests were two-tailed, at 95% confidence interval and a p < 0.05 was considered significant. All statistical analyses were performed using the GraphPad Prism software.
All data generated or analyzed during this study are included in this published article (and its Supplementary Information Files).
Vivino, F. B. et al. Sjogren’s syndrome: An update on disease pathogenesis, clinical manifestations and treatment. Clin. Immunol. 203, 81–121 (2019).
Xiao, F. et al. Animal models of Sjogren’s syndrome: an update. Clin. Exp. Rheumatol. 37, 209–216 (2019).
Markle, J. G. et al. Sex differences in the gut microbiome drive hormone-dependent regulation of autoimmunity. Science. 339, 1084–1088 (2013).
Hanninen, A. et al. Akkermansia muciniphila induces gut microbiota remodelling and controls islet autoimmunity in NOD mice. Gut. 67, 1445–1453 (2018).
Kim, J. W. et al. Metformin improves salivary gland inflammation and hypofunction in murine Sjogren’s syndrome. Arthritis. Res. Ther. 21, 136, https://doi.org/10.1186/s13075-019-1904-0 (2019).
Wieczorek, G. et al. Blockade of CD40-CD154 pathway interactions suppresses ectopic lymphoid structures and inhibits pathology in the NOD/ShiLtJ mouse model of Sjogren’s syndrome. Ann. Rheum. Dis. 78, 974–978 (2019).
Zeng, M. et al. Restoration of CFTR Activity in Ducts Rescues Acinar Cell Function and Reduces Inflammation in Pancreatic and Salivary Glands of Mice. Gastroenterol. 153, 1148–1159 (2017).
Wang, C. S., Maruyama, C. L., Easley, J. T., Trump, B. G. & Baker, O. J. AT-RvD1 Promotes Resolution of Inflammation in NOD/ShiLtJ mice. Sci. Rep. 7, 45525, https://doi.org/10.1038/srep45525 (2017).
Zhou, J., Jin, J. O., Kawai, T. & Yu, Q. Endogenous programmed death ligand-1 restrains the development and onset of Sjgren’s syndrome in non-obese diabetic mice. Sci. Rep. 6, 39105, https://doi.org/10.1038/srep39105 (2016).
Inoue, H. et al. Resveratrol improves salivary dysfunction in a non-obese diabetic (NOD) mouse model of Sjogren’s syndrome. J. Clin. Biochem. Nutr. 59, 107–112 (2016).
Tran, S. D. et al. Reversal of Sjogren’s-like syndrome in non-obese diabetic mice. Ann. Rheum. Dis. 66, 812–814 (2007).
Bagavant, H., et al. A Method for the Measurement of Salivary Gland Function in Mice. Journal of visualized experiments. J. Vis. Exp. 131, https://doi.org/10.3791/57203 (2018).
Jonsson, M. V., Delaleu, N., Brokstad, K. A., Berggreen, E. & Skarstein, K. Impaired salivary gland function in NOD mice: association with changes in cytokine profile but not with histopathologic changes in the salivary gland. Arthritis Rheum. 54, 2300–2305 (2006).
Verhulst, M. J. L., Loos, B. G., Gerdes, V. E. A. & Teeuw, W. J. Evaluating All Potential Oral Complications of Diabetes Mellitus. Front. Endocrinol. 10, 56, https://doi.org/10.3389/fendo.2019.00056 (2019).
Wang, J. et al. A mutation in the insulin 2 gene induces diabetes with severe pancreatic beta-cell dysfunction in the Mody mouse. J. Clin. Invest. 103, 27–37 (1999).
Yeh, C. K. et al. Hyperglycemia and xerostomia are key determinants of tooth decay in type 1 diabetic mice. Lab. Invest. 92, 868–882 (2012).
Fedirko, N. V. et al. Changes in functioning of rat submandibular salivary gland under streptozotocin-induced diabetes are associated with alterations of Ca2+ signaling and Ca2+ transporting pumps. Biochim. Biophys. Acta. 1762, 294–303 (2006).
Cha, S. et al. A dual role for interferon-gamma in the pathogenesis of Sjogren’s syndrome-like autoimmune exocrinopathy in the nonobese diabetic mouse. Scand. J. Immunol. 60, 552–565 (2004).
Augusto, K. L. et al. Metabolic syndrome in Sjogren’s syndrome patients: a relevant concern for clinical monitoring. Clin. Rheumatol. 35, 639–647 (2016).
Roescher, N. et al. Temporal changes in salivary glands of non-obese diabetic mice as a model for Sjögren’s syndrome. Oral Dis. 18, 96–106 (2012).
Zhou, J., Jin, J. O., Kawai, T. & Yu, Q. Endogenous programmed death ligand-1 restrains the development and onset of Sjӧgren’s syndrome in non-obese diabetic mice. Sci. Rep. 6, https://doi.org/10.1038/srep39105 (2016).
Barr, J. Y., Wang, X., Kreiger, P. A. & Lieberman, S. M. Salivary-gland-protective regulatory T-cell dysfunction underlies female-specific sialadenitis in the non-obese diabetic mouse model of Sjögren syndrome. Immunology. 155, 225–237 (2018).
Braley-Mullen, H. & Yu, S. NOD.H-2h4 mice: an important and underutilized animal model of autoimmune thyroiditis and Sjogren’s syndrome. Adv. Immunol. 126, 1–43 (2015).
Kiripolsky, J. et al. Systemic manifestations of primary Sjogren’s syndrome in the NOD.B10Sn-H2(b)/J mouse model. Clin. Immunol. 183, 225–232 (2017).
Szczerba, B. M. et al. Interaction between innate immunity and Ro52-induced antibody causes Sjogren’s syndrome-like disorder in mice. Ann. Rheum. Dis. 75, 617–22 (2016).
This work was supported by the National Institute of Dental and Craniofacial Research (DE025030) and Oklahoma Medical Research Foundation. The authors acknowledge the excellent technical support from the OMRF Imaging Core Facility for tissue sectioning and image acquisition. We thank the Laboratory for Molecular Biology and Cytometry Research at Oklahoma University Health Sciences Center for the use of the Core Facility, which provided Nanostring gene expression service.
The authors declare no competing interests.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Allushi, B., Bagavant, H., Papinska, J. et al. Hyperglycemia and Salivary Gland Dysfunction in the Non-obese Diabetic Mouse: Caveats for Preclinical Studies in Sjögren’s Syndrome. Sci Rep 9, 17969 (2019). https://doi.org/10.1038/s41598-019-54410-9
This article is cited by
Stem Cell Research & Therapy (2021)